我们表明,现成的α-酰胺醛是分子间Rh催化炔烃加氢酰化反应的有效底物。催化剂[Rh(dppe)(C 6 H 5 F)] [BAr F 4 ]具有良好的反应活性,可将各种醛和炔烃用作底物,从而提供α-酰胺酮产品。实现了高产率和高水平的区域选择性。使用α-酰胺醛作为底物可确定1,4-二羰基可以用作Rh催化加氢酰化反应中的控制基团。
[EN] NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS<br/>[FR] NOUVEAUX COMPOSES D'OXABISPIDINE ET LEUR UTILISATION DANS LE TRAITEMENT D'ARYTHMIES CARDIAQUES
申请人:ASTRAZENECA AB
公开号:WO2005123747A1
公开(公告)日:2005-12-29
There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
Reactions of Aziridines with Acetyl Chloride and Related Compounds
作者:Itaru Okada、Toshio Takahama、Rokuro Sudo
DOI:10.1246/bcsj.43.2591
日期:1970.8
When aziridines (1) were treated with acetyl compounds, such as acetylchloride, acetic acid, acetic anhydride, and thioacetic acid, the corresponding acetamide derivatives were obtained in good yields. In the case of acetylchloride, some derivatives of N-(2-chloroethyl)acetamide (5) were found to be unstable in the face of moisture; they were easily hydrolyzed to give N-(2-hydroxyethyl) acetamide
Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
申请人:Bjore Annika
公开号:US20080319198A2
公开(公告)日:2008-12-25
There is provided compounds of formula I,
wherein R
1
, R
2
, R
4
, R
41
to R
46
, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias
申请人:Bjore Annika
公开号:US20070259864A1
公开(公告)日:2007-11-08
There is provided compounds of formula I, wherein R
1
, R
2
, R
4
, R
41
to R
46
, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
Oxabispidine compounds and their use in the treatment of cardiac arrhythmias
申请人:AstraZeneca AB
公开号:US07354917B2
公开(公告)日:2008-04-08
There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular a trial and ventricular arrhythmias.